Diagnose.me
Diagnose.me is a Netherlands-based digital health platform founded in 2012 that connects patients from 80+ countries with internationally vetted medical specialists for expert second opinions, personalised oncology, and pathology review, distributed primarily through B2B partnerships with 25+ insurance companies and banks.
- Company typePrivate
- Founded2012
- HeadquartersAlkmaar, Netherlands
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Diagnose.me does
Diagnose.me is a digital health platform founded in 2012 and headquartered in Rumpt, the Netherlands, that connects patients with internationally vetted medical specialists for expert second opinions. The platform operates three core services: an Expert Medical Opinion offering where patients select a specialist, upload medical data, and receive a detailed written report with two free follow-up questions; Personalised Oncology, which provides targeted cancer treatment recommendations based on molecular and genetic tumour profiling delivered through partners Oncompass and Multiplex DX; and Pathology Review via the biopsy.me sub-brand, an independent biopsy analysis service connecting patients to a network of board-certified pathologists. Specialist credentials are gated by a Medical Advisory Board of ten world-renowned radiology and surgery experts who enforce strict academic, clinical, and communication criteria before admission to the network. The platform supports 25+ languages and serves patients from 80+ countries.
The underlying technology combines a multilingual marketplace and case-management workflow with AI-assisted radiology tooling used by specialists to interpret medical images, plus integrations with third-party molecular diagnostics providers for oncology. Diagnose.me holds no patents or proprietary AI models disclosed in the source data, and its technology moat centres on the curated specialist network, Medical Advisory Board vetting, and accumulated case corpus rather than owned model IP.
Diagnose.me monetises through two primary channels. The dominant go-to-market is B2B partnership licensing with 25+ insurance companies and banks (KBC, Raiffeisen, UniCredit, NN, Hannover Re, Vienna Insurance Group brands, etc.) across 15+ Central and Eastern European countries, where services are embedded as employee benefits or policy add-ons reaching 3.5M+ members. A secondary direct-to-consumer channel allows individual patients to self-serve and pay per consultation, with specialists setting their own fees and turnaround times, while oncology tests are priced at €2,500-€3,900 per case. The company is privately held, has raised approximately $638K of disclosed venture funding across 2012-2015, and operates with 11-50 employees.
Diagnose.me firmographics
Firmographics- Name
- Diagnose.me
- Legal name
- Diagnose.me BV
- Website
- https://diagnose.me
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Diagnose.me is a Netherlands-based digital health platform founded in 2012 that connects patients from 80+ countries with internationally vetted medical specialists for expert second opinions, personalised oncology, and pathology review, distributed primarily through B2B partnerships with 25+ insurance companies and banks.
- Ownership category
- akta.pro rank
Diagnose.me industry classification
Industry- Product category
- Telemedicine Medical Second Opinion Services
- NAICS
- Ambulatory Health Care Services (621)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Second Opinion & Expert Matching Platforms (HLALALAC)
- akta.pro secondary industries
- Second Opinion & Expert Medical Review Platforms (HLALADAI), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Diagnose.me is headquartered
LocationHeadquarters
- HQ city
- Alkmaar
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Diagnose.me business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Expert Medical Opinion Consultation Fees: Specialists set their own consultation fees and delivery times. Patients pay for expert medical opinions from international specialists across various medical specializations.
- Personalised Oncology Testing: Diagnostic testing services for cancer treatment personalization. Providers include Oncompass (€3900) and Multiplex DX (€2500), providing comprehensive molecular profiling and treatment recommendations based on tumor genetic features.
- Pathology Review Service: Biopsy evaluation service provided through biopsy.me network of international pathologists, analyzing tumor specimens to determine cancer subtypes.
- B2B Partnership Licensing: Insurance companies and banks integrate Diagnose.me services as employee benefits or policy add-ons. Partnership models include free benefits for customers, paid add-ons, or themed packages linked to specific policies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Oncompass comprehensive molecular profiling |
| Unit Pricing | Pay-as-you-go | Multiplex DX breast cancer testing |
| Unit Pricing | Pay-as-you-go | Expert Medical Opinion - Specialist Consultation |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Diagnose.me product offering
Product offeringCore offering
Diagnose.me operates a digital health platform that connects patients with a curated network of international medical specialists for expert second opinions, personalised oncology treatment guidance, and pathology review. Patients select specialists, upload medical data, and receive detailed reports in their preferred language, with services delivered via a web-based platform supporting 25+ languages. The company also offers B2B partnership integrations where insurance companies and banks bundle Diagnose.me services as employee benefits or policy add-ons.
Product overview
Diagnose.me is a digital health platform that provides a curated network of international medical specialists offering expert second opinions. The platform operates three interconnected services: Expert Medical Opinion as the core product for general diagnostic consultations, Personalised Oncology for targeted cancer treatment recommendations based on molecular profiling (providers include Oncompass and Multiplex DX), and Pathology Review for independent biopsy analysis through biopsy.me. All services are delivered via a web-based platform with support for 25+ languages, connecting patients from 80+ countries with specialists from top international hospitals and institutions.
Differentiator
Problem solved
Functional benefit
Brands
- biopsy.me: Telepathology service provided by Diagnose.me that connects patients to an international network of board-certified pathologists for biopsy reviews.
Products and services
- Expert Medical Opinion
- Personalised Oncology
- Pathology Review
Quantifiable outcome
- 70% of sales agents report higher conversion rates when offering Diagnose.me services
- +4 more outcomes
Companies that use Diagnose.me
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles4 records
Diagnose.me technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature2 records
Diagnose.me partnerships and signals
Strategic signalPartnerships
31 partnerships are on record, tiered core and major.
- Bulstrad Life (Vienna Insurance Group)coreMajor insurance partner integrating Diagnose.me services into their product offerings. Bulstrad Life, part of Vienna Insurance Group, offers second medical opinion as part of their life insurance products.
- TAS LifecoreUkrainian life insurance company providing Diagnose.me services to policyholders. Partnership has delivered services to thousands of clients since inception.
- NN SlovakiacoreDutch insurance company offering Diagnose.me as health benefits package to Slovak clients. Over 10,000 clients benefited in first three years.
- AsirommajorInsurance company partner providing second medical opinion services to policyholders.
- BTA InsurancemajorInsurance partner offering Diagnose.me services to customers.
- CrosigmajorCroatian insurance company partner.
- DonarismajorMoldovan insurance company partner.
- Global Assistance PolandmajorAssistance services provider in Poland.
- GPIHmajorInsurance partner.
- Hannover RecoreMajor reinsurance company partner providing support for insurance products.
- IRAOmajorInsurance partner.
- KBC GroupcoreBelgian banking and insurance group with presence across CEE.
- Komunalna poistovnamajorSlovak insurance company partner.
- KooperativamajorSlovak insurance company partner (Vienna Insurance Group).
- Liga InsurancemajorInsurance company partner.
- Makedonija InsurancemajorNorth Macedonian insurance partner.
- mbankmajorPolish banking institution partner offering Diagnose.me services.
- Pasha LifemajorAzerbaijani life insurance partner.
- Postbank BulgariamajorBulgarian bank partner.
- RaiffeisencoreInternational banking group with presence across CEE.
- Tatra BankacoreSlovak banking institution partner offering Diagnose.me services through benefits programs.
- UniCredit BankcoreInternational banking group partner in Slovakia and Czech Republic.
- Union HungarymajorHungarian insurance company partner.
- UniqamajorAustrian insurance group with CEE presence.
- Vienna LifecoreLife insurance brand of Vienna Insurance Group.
- biopsy.mecoreTelepathology service provider connecting patients to an international network of board-certified pathologists for comprehensive and precise diagnostic evaluations.
- OncompasscoreProvider of comprehensive molecular profiling and personalised therapy planning for cancer treatment. Services include clinical interpretation and tumour board access for EU patients.
- Multiplex DXcoreProvider of diagnostic tests for breast cancer, available in EU countries with reports in English or Slovak.
- Acıbadem Healthcare GroupcoreTop international hospital and institution part of Diagnose.me's global medical network providing specialist expertise.
- Rambam Health Care CampuscoreLeading medical institution in Diagnose.me's global specialist network.
- Dr. Berezin Medical CentercoreInternational medical institution providing specialists to Diagnose.me network.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Diagnose.me competitors and assessment
Company assessmentDirect peers
- Best Doctors (Teladoc Health): Best Doctors pioneered the expert medical second opinion model and is now part of Teladoc Health; it is the closest direct competitor, offering cross-border expert reviews to insurance and employer clients globally.
- MediGuide: Global second medical opinion provider primarily serving insurance and financial services clients; overlaps directly with Diagnose.me's insurance-embedded B2B model across multiple geographies.
- Advance Medical: Telemedicine and expert medical opinion provider serving insurers, employers and governments worldwide; competes with Diagnose.me in cross-border expert opinion delivery to payer clients.
- WorldCare International: Provides international medical second opinions and e-health services to insurance, assistance and corporate clients, comparable in cross-border expert review delivery and payer partnerships.
- 2nd.MD: US-based second opinion service acquired by Accolade, connecting employees of large US employers with specialist experts for case reviews; directly comparable in product, B2B distribution model and clinical opinion flow.
- Medix: Global medical management and second opinion company serving insurance and corporate clients across multiple continents; comparable in B2B payer-embedded second opinion and care navigation.
Broad incumbents
- AXA Health Second Medical Opinion: AXA's embedded second opinion benefit available to policyholders via partnerships; a broader incumbent offering overlapping second opinion capabilities as part of a much larger insurance and health portfolio.
- Teladoc Health: Largest global telehealth platform offering virtual care, expert medical services and second opinions; broader incumbent whose portfolio includes direct competitors (Best Doctors) to Diagnose.me's expert review offering.
- Cleveland Clinic MyConsult: Online medical second opinion service from Cleveland Clinic offering expert reviews for a fee; an academic-medical-center incumbent whose offerings compete for the same patient-paid second opinion demand.
- Doctoralia (Docplanner Group): Global healthcare marketplace connecting patients with specialists and enabling online consultations; broader incumbent in patient-specialist matching with overlapping online second opinion use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Diagnose.me social profiles
Digital presenceDiagnose.me financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diagnose.me leadership team
Management profileNumber of profiles
Profiles9 records
Diagnose.me funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diagnose.me M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diagnose.me
What does Diagnose.me do?
Diagnose.me operates a digital health platform that connects patients with a curated network of international medical specialists for expert second opinions, personalised oncology treatment guidance, and pathology review. Patients select specialists, upload medical data, and receive detailed reports in their preferred language, with services delivered via a web-based platform supporting 25+ languages. The company also offers B2B partnership integrations where insurance companies and banks bundle Diagnose.me services as employee benefits or policy add-ons.
Is Diagnose.me a public or private company?
Diagnose.me is a private company. It is classified as venture growth investor backed and is currently operating.
When was Diagnose.me founded?
Diagnose.me was founded in 2012. It employs 11 to 50 people.
Where is Diagnose.me based?
Diagnose.me is headquartered in Alkmaar, Netherlands, in the Europe region.
How does Diagnose.me make money?
Four revenue lines are on record. Expert Medical Opinion Consultation Fees are the primary driver. The others are personalised Oncology Testing, pathology Review Service and B2B Partnership Licensing.
Who are Diagnose.me's main competitors?
Direct peers on record are Best Doctors (Teladoc Health), MediGuide, Advance Medical, WorldCare International, 2nd.MD and Medix. Broad incumbents are AXA Health Second Medical Opinion, Teladoc Health, Cleveland Clinic MyConsult and Doctoralia (Docplanner Group).
Does Diagnose.me have an API?
No public API is recorded for Diagnose.me.
What industry is Diagnose.me in?
Diagnose.me's product category is Telemedicine Medical Second Opinion Services. Its primary akta.pro industry code is HLALALAC, Second Opinion & Expert Matching Platforms, with a secondary code of HLALADAI, Second Opinion & Expert Medical Review Platforms. Its NAICS code is 621 and its SIC code is 8000.